Cocrystal Pharma, Inc. - 10-Q Filing
Cocrystal Pharma reports Q3 2026 net loss of $3.4M on increased R&D spending and declining cash reserves.
Tickers: $COCP
Read the full article at SEC EDGAR
Part of the story Lightwave Logic Reports Q3 2026 Financial Results and Delays Volume Production to 2028 (2 articles)